Genprex receives conditional US FDA acceptance for the treatment of non-small cell lung cancer

▴ Genprex receives conditional US FDA acceptance for the treatment of non-small cell lung cancer
Genprex receives conditional FDA acceptance of proprietary name REQORSA for lead drug candidate for the treatment of non-small cell lung cancer

Genprex, Inc., a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted the proprietary name REQORSA for its lead drug candidate in development for the treatment of non-small cell lung cancer, known previously by the laboratory designation GPX-001.

The name REQORSA, was developed in accordance with the FDA’s guidance for the submission and evaluation of proprietary names. The Company selected the name based on a comprehensive and disciplined review of name candidates, including a research study of healthcare practitioners across the U.S. to ensure accurate prescription and safety interpretation of the name.

“We are very pleased to receive FDA’s conditional acceptance of our proprietary name, REQORSA, which is a necessary step toward being able to market our lead drug candidate for non-small cell lung cancer,” said Rodney Varner, President and Chief Executive Officer of Genprex. “This name approval also marks an important milestone in our overall branding strategy, giving us a unique, easily understood name people can associate with the Genprex brand and mission.”

Genprex will resubmit its proprietary name for FDA final review upon completion of all required clinical trials and prior to the submission of a Biologics License Application. Final approval of the REQORSA brand name is conditional on FDA approval of the product candidate.

REQORSA uses the company’s unique, proprietary ONCOPREX nanoparticle delivery system, which delivers cancer-fighting genes by encapsulating them into nanoparticles, which are then administered intravenously and taken up by tumour cells where they express proteins that are missing or found in low quantities. In January 2020, the FDA granted Fast Track Designation for REQORSA in combination with AstraZeneca’s Tagrisso for the treatment of non-small cell lung cancer.

Tags : #GenprexInc #LatestNewsonGenprex30thOct #LatestPharmaNews230thOct #LatestUSFDAClearance30thOct #RodneyVarner #AstraZeneca #LungCancer

About the Author

Team Medicircle

Related Stories

Loading Please wait...


Trending Now

Hritik roshan was a survivor of Brain tumourAugust 09, 2022
Does your child gets scared when left alone at home? Learn how to save him from separation anxiety disorderAugust 08, 2022
4 mistakes to avoid increasing uric acid in the bodyAugust 08, 2022
Vitamin B complex is very important for the nervous system and brain, know its benefits and sourcesAugust 08, 2022
Eyestem raises $6.4M in Series A roundAugust 08, 2022
Why are your regular health check-ups so important?August 08, 2022
Switch to rash free periods with FemisafeAugust 06, 2022
Best Solutions for Allergy TreatmentAugust 06, 2022
Best Solutions for Allergy Treatment - MedicircleAugust 06, 2022
One of the effective way of losing fat is LiposuctionAugust 05, 2022
Shocking to know these facts about ketamine-an anesthesia drugAugust 05, 2022
Unheard astonishing health benefits of King fish salmon (Rawas)August 05, 2022
Troubled by Anxiety? Learn easy tips to removeAugust 05, 2022
Monkeypox: Know the cause of this rare disease, its symptoms, and important things related to its treatmentAugust 05, 2022
Dial HealtHMED provides quality innovative products for beauty and personal careAugust 05, 2022
Ease your period’s symptoms with these do’s and don'tsAugust 04, 2022
9 solutions to increase the memory of childrenAugust 04, 2022
Diet plan for Blood Pressure ControlAugust 04, 2022
7 Symptoms of Chest InfectionAugust 04, 2022
Is vitamin k beneficial for preventing excessive bleeding?August 04, 2022